



## Clinical trial results: Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine Summary

EudraCT number	2020-000890-25
Trial protocol	FR
Global end of trial date	25 March 2020

### Results information

Result version number	v1 (current)
This version publication date	01 November 2022
First version publication date	01 November 2022

### Trial information

#### Trial identification

Sponsor protocol code	202002102
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Fondation Méditerranée Infection
Sponsor organisation address	19-21 boulevard jean moulin, marseille, France, 13005
Public contact	IHU Méditerranée Infection, Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection, 0033 4 13 73 23 47, direction.ihu@mediterranee-infection.com
Scientific contact	IHU Méditerranée Infection, Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection, 0613637651 4 13 73 23 47, direction.ihu@mediterranee-infection.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	05 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 March 2020
Global end of trial reached?	Yes
Global end of trial date	25 March 2020
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To shorten the period of virus shedding and thus contagion

Protection of trial subjects:

Monitoring will be as usual for short-term Plaquenil prescriptions, essentially three times a week monitoring of blood sugar and potassium levels. Drugs which may prolong the QT should only be prescribed if absolutely necessary.

In addition, serum hydroxychloroquine levels should be monitored twice a week in order to control residual levels and to adapt the dosage (target 1 to 2 µg/L).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 March 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	France: 24
Worldwide total number of subjects	24
EEA total number of subjects	24

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	19
From 65 to 84 years	5
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Patients hospitalised in the APMH, for whom a diagnosis of SARS-CoV2 respiratory infection will be made on a pharyngeal swab or a deep respiratory sample by the IHU laboratory, will be contacted and offered to participate in the protocol, after having been expressly informed of the risks and expected benefits of Hydroxychloroquine treatment

### Pre-assignment

Screening details:

Patients with coronavirus disease COVID-19

Adults (18-64 years)

Elderly ( $\geq 65$  years)

### Period 1

Period 1 title	5th march 2020 (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Experimental group
-----------	--------------------

Arm description:

Patients treated by hydroxychloroquine

Arm type	Experimental
Investigational medicinal product name	Plaquenil 200 mg, comprimé pelliculé
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

600 mg per day

<b>Number of subjects in period 1</b>	Experimental group
Started	24
Completed	21
Not completed	3
Consent withdrawn by subject	1
intensive care unit on day 1 for complications	2

## Baseline characteristics

### Reporting groups

Reporting group title	5th march 2020
-----------------------	----------------

Reporting group description: -

Reporting group values	5th march 2020	Total	
Number of subjects	24	24	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	19	19	
From 65-84 years	5	5	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	10	10	
Male	14	14	

## End points

### End points reporting groups

Reporting group title	Experimental group
Reporting group description:	
Patients treated by hydroxychloroquine	

### Primary: Results of SARS-COV2 virus detection at day 1

End point title	Results of SARS-COV2 virus detection at day 1 <sup>[1]</sup>
-----------------	--

End point description:

21 patients analysed for the primary endpoint "virus detection". These were the 21 patients who took the experimental treatment in accordance with the conditions set out in the clinical trial (dosage, duration, hospitalisation at the IHU, etc.).

End point type	Primary
----------------	---------

End point timeframe:

Day 1 after treatment

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: It is a descriptive study with 1 arm, there is no inference statistics results.

<b>End point values</b>	Experimental group			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: 24 %	21			

### Statistical analyses

No statistical analyses for this end point

### Primary: Results of SARS-COV2 virus detection at day 4

End point title	Results of SARS-COV2 virus detection at day 4 <sup>[2]</sup>
-----------------	--

End point description:

21 patients analysed for the primary endpoint "virus detection". These were the 21 patients who took the experimental treatment in accordance with the conditions set out in the clinical trial (dosage, duration, hospitalisation at the IHU, etc.).

End point type	Primary
----------------	---------

End point timeframe:

Day 4 after treatment

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: It is a descriptive study with 1 arm, there is no inference statistics results.

<b>End point values</b>	Experimental group			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: 52 %	21			

## Statistical analyses

No statistical analyses for this end point

### Primary: Results of SARS-COV2 virus detection at day 7

End point title	Results of SARS-COV2 virus detection at day 7 <sup>[3]</sup>
-----------------	--

End point description:

21 patients analysed for the primary endpoint "virus detection". These were the 21 patients who took the experimental treatment in accordance with the conditions set out in the clinical trial (dosage, duration, hospitalisation at the IHU, etc.).

End point type	Primary
----------------	---------

End point timeframe:

Day 7 after treatment

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: It is a descriptive study with 1 arm, there is no inference statistics results.

<b>End point values</b>	Experimental group			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: 60 %	24			

## Statistical analyses

No statistical analyses for this end point

### Primary: Results of SARS-COV2 virus detection at day 14

End point title	Results of SARS-COV2 virus detection at day 14 <sup>[4]</sup>
-----------------	---

End point description:

21 patients analysed for the primary endpoint "virus detection". These were the 21 patients who took the experimental treatment in accordance with the conditions set out in the clinical trial (dosage, duration, hospitalisation at the IHU, etc.).

End point type	Primary
----------------	---------

End point timeframe:

Day 14 after treatment

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: It is a descriptive study with 1 arm, there is no inference statistics results.

<b>End point values</b>	Experimental group			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: 100 %	21			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

- one nausea
- 2 patients were transferred to the intensive care unit on day 1 for complications of the disease (adaptation or discontinuation of the experimental treatment).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

### Reporting groups

Reporting group title	Experimental group
-----------------------	--------------------

Reporting group description: -

Serious adverse events	Experimental group		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 24 (8.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Respiratory, thoracic and mediastinal disorders			
Intensive care			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Experimental group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 24 (4.17%)		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported